Coulter Partners places Chief Executive Officer at Alethio Therapeutics

Health, science and technology recruiter Coulter Partners successfully completed a search assignment for Alethio Therapeutics – formerly known as Alethiomics – and is pleased to announce the placement of Dr. Rohit Batta as Chief Executive Officer.

Rohit Batta joins Alethio Therapeutics from Ferring Ventures, where he served as Managing Director and Head of the group company. Previously, he was Chief Medical Officer at Vicore Pharma and also held senior leadership roles at GSK, where he led the clinical strategy for haemoglobinopathy gene therapies and played a pivotal role in launching the world’s first gene therapy for a pediatric rare disease – an achievement that earned his team a prestigious Prix Galien award. Rohit brings 20 years of industry experience in translating breakthrough science into therapies and strategic partnerships. He began his career as a physician in the UK’s National Health Service, and has worked across multiple clinical specialties including oncology.

Rohit Batta, CEO of Alethio Therapeutics, said:

With no curative options, MPNs expose patients to ongoing risk of disease evolution and poor outcomes. Alethio Therapeutics is entering a new chapter with the ambition and leadership to deliver the first disease-modifying therapies for MPNs. While current treatments are largely symptomatic, our unique expertise and approach enable us to directly target the drivers of disease progression, with the aim of shifting the treatment paradigm and transforming outcomes for patients. It is an exciting time to be joining Alethio Therapeutics, and I look forward to leading our team as we advance our pipeline.

Mark Throsby, non-executive Director at Alethio Therapeutics, said:

We set out to find a CEO who was a strong business leader, possessing acute commercial acumen alongside the ability to deeply understand our innovative science to guide our strategy through the next phase of growth. Coulter Partners immediately grasped this brief. Their diligent search successfully identified a visionary who not only met all our criteria, but who also clicked immediately with the founders and the Board. We appreciate their expertise in delivering this critical placement.